Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

Levodopa is effective for the motor symptoms of Parkinson's disease (PD), but is associated with motor fluctuations and dyskinesia. Many patients require add-on therapy to improve motor fluctuations without exacerbating dyskinesia. The objective of this Phase III, multicenter, double-blind, pla...

Full description

Bibliographic Details
Main Authors:	Borgohain, Rupam, Szasz, J, Stanzione, P, Meshram, C, Bhatt, M, Chirilineau, D, Stocchi, F, Lucini, V, Giuliani, R, Forrest, E, Rice, P, Anand, R
Format:	Online
Language:	English
Published:	BlackWell Publishing Ltd 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285943/

Similar Items

Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLE
by: Cattaneo, Carlo, et al.
Published: (2016)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
by: Stocchi, Fabrizio, et al.
Published: (2016)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
by: Bette S, et al.
Published: (2018-09-01)

Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
by: Müller, Thomas
Published: (2016)

Investigational agents in the treatment of Parkinson’s disease: focus on safinamide
by: Malek, Naveed M, et al.
Published: (2012)

Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease
by: Virmani, Tuhin, et al.
Published: (2016)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
by: Loprete, Luca, et al.
Published: (2016)

Mortality in Levodopa-Treated Parkinson's Disease
by: Morgan, John C., et al.
Published: (2014)

Levodopa-Responsive Benign Tremulous Parkinsonism
by: Kano, Osamu, et al.
Published: (2013)

Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis
by: Cattaneo, Carlo, et al.
Published: (2015)

Modulation of Habit Formation by Levodopa in Parkinson's Disease
by: Marzinzik, Frank, et al.
Published: (2011)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
by: Antonini, Angelo
Published: (2009)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
by: Bargiotas, Panagiotis, et al.
Published: (2013)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
by: Schaeffer, Eva, et al.
Published: (2016)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
by: Cerasa, Antonio, et al.
Published: (2015)

Improvement of Primary Writing Tremor in Parkinson’s Disease with Carbidopa/Levodopa
by: Battista, James P., et al.
Published: (2015)

Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
by: Lee, Phil Hyu, et al.
Published: (2011)

Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
by: Mao, Zhongping Lily, et al.
Published: (2016)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
by: Kuoppamäki, Mikko, et al.
Published: (2015)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
by: Othman, Ahmed A, et al.
Published: (2014)

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
by: Guridi, J., et al.
Published: (2012)

Resting‐state connectivity predicts levodopa‐induced dyskinesias in Parkinson's disease
by: Herz, Damian M., et al.
Published: (2016)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
by: Herz, Damian M., et al.
Published: (2014)

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study
by: Stocchi, Fabrizio, et al.
Published: (2015)

Chimeric Agents Derived from the Functionalized Amino Acid, Lacosamide, and the α-Aminoamide, Safinamide: Evaluation of Their Inhibitory Actions on Voltage-Gated Sodium Channels, and Antiseizure and Antinociception Activities and Comparison with Lacosamide and Safinamide
by: Park, Ki Duk, et al.
Published: (2014)

Neuropathy in Parkinson’s Disease Patients with Intestinal Levodopa Infusion versus Oral Drugs
by: Jugel, Constanze, et al.
Published: (2013)

Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson’s disease
by: Cui, Guiyun, et al.
Published: (2013)

Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease
by: Kim, Ji Hee, et al.
Published: (2015)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
by: Pahwa, Rajesh, et al.
Published: (2015)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
by: Antonini, Angelo, et al.
Published: (2016)

Three Cases of Levodopa-Resistant Parkinsonism After Radiation Therapy
by: Mehanna, Raja, et al.
Published: (2016)

Levodopa medication improves incidental sequence learning in Parkinson's disease
by: Beigi, M., et al.
Published: (2016)

Efficacy and motor complications of original and generic levodopa in Parkinson’s disease treatment
by: Kasemsap, Narongrit, et al.
Published: (2016)

Pharmacokinetics of Levodopa before and after Gastrointestinal Resection in Parkinson's Disease
by: Nagayama, Hiroshi, et al.
Published: (2015)

Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment
by: Günaydın, Zeki Yüksel, et al.
Published: (2016)

Factors Predictive of the Development of Levodopa-Induced Dyskinesia and Wearing-Off in Parkinson's Disease
by: Rajput, Ali H
Published: (2014)

Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease
by: Krishna, Rakhee, et al.
Published: (2014)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
by: Teng, Long, et al.
Published: (2014)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
by: Zhang, Jinglin, et al.
Published: (2016)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
by: Mao, Zhongping, et al.
Published: (2013)